Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases
The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucagon-like peptide-1 (GLP-1) is a hormone belonging to the incretin family, and its receptors (GLP-1Rs) can be found in pancreatic cells and in vascular endothelium. Interestingly, GLP-1Rs are found in the neuronal cell body and dendrites in the central nervous system (CNS), in particular in the hypothalamus, hippocampus, cerebral cortex and olfactory bulb. Several studies have shown the importance of both insulin and GLP-1 signalling on cognitive function, and many preclinical studies have been performed to evaluate the potential protective role of GLP-1 on the brain. Here we review the underlying mechanism of insulin and GLP-1 signalling in the CNS, as well as the preclinical data for the use of GLP-1 analogues such as liraglutide, exenatide and lixisenatide in neurodegenerative diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to multiple preclinical studies, GLP-1 RAs reduce amyloid deposition and glial cell activation and stimulate synaptic neurotransmitter release to induce long-term potentiation (LTP) in AD models.426”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [426]
Citations
Cites
1 retracted
Rampersaud, N., Harkavyi, A., Giordano, G., Lever, R., Whitton, J., & Whitton, P. S. (2012) · Neuropeptides · doi:10.1016/j.npep.2012.07.004 · Cited by 34
Retracted2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
Alzheimer’s disease is type 3 diabetes—Evidence reviewed
de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158
2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
Synaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657
De Felice, F. G., & Ferreira, S. T. (2014) · Diabetes · doi:10.2337/db13-1954 · Cited by 639
Identification of insulin in rat brain.
Havrankova, J., Schmechel, D., Roth, J., & Brownstein, M. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.11.5737 · Cited by 605
Watson, G. S. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 597
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
Berendsen, A. A. M., Kang, J. H., van de Rest, O., Jankovic, N., Kampman, E., Kiefte-de Jong, J. C., Franco, O. H., Ikram, M. A., Pikhart, H., Nilsson, L. M., et al. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000464269 · Cited by 562
Conversion of amyloid positive and negative MCI to AD over 3 years: An 11 C-PIB PET study
Okello, A., Koivunen, J., Edison, P., Archer, H. A., Turkheimer, F. E., Någren, K., Bullock, R., Walker, Z., Kennedy, A., Fox, N. C., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b23564 · Cited by 527
Self-citationEdison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513
Self-citationHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Morales, I., Guzmán-MartÃnez, L., Cerda-Troncoso, C., FarÃas, G. A., & Maccioni, R. B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00112 · Cited by 490
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms
Sastre, M., Klockgether, T., & Heneka, M. T. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.014 · Cited by 426
Chiu, S.-L., Chen, C.-M., & Cline, H. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.014 · Cited by 425
Glucose tolerance status and risk of dementia in the community: The Hisayama Study
Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S., & Kiyohara, Y. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0435 · Cited by 420
Hippocampal memory processes are modulated by insulin and high-fat-induced insulin resistance
McNay, E. C., Ong, C. T., McCrimmon, R. J., Cresswell, J., Bogan, J. S., & Sherwin, R. S. (2010) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2010.02.002 · Cited by 397
Varnum, M. M., & Ikezu, T. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0181-2 · Cited by 394
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
How does brain insulin resistance develop in Alzheimer's disease?
De Felice, F. G., Lourenco, M. V., & Ferreira, S. T. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.004 · Cited by 337
HENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317
Heneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Dewachter, I., Walter, J., Klockgether, T., & Van Leuven, F. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-22 · Cited by 309
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
Jaturapatporn, D., Isaac, M. G. E. K. N., McCleery, J., & Tabet, N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006378.pub2 · Cited by 299
P1‐071: Intensity of dementia through latent variable modelling (I‐DeLV) in the AIBL cohort
Burnham, S., Graham, P., Wilson, B., Ames, D., Macaulay, L., Martins, R., Masters, C., Maruff, P., Rowe, C., Szoeke, C., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.347 · Cited by 292
Zhao, W.-Q., & Townsend, M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.014 · Cited by 291
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J.-C., & Olefsky, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710402105 · Cited by 239
McNay, E. C., & Recknagel, A. K. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.005 · Cited by 229
Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?
Hoyer, S., Oesterreich, K., & Wagner, O. (1988) · Journal of Neurology · doi:10.1007/bf00314304 · Cited by 227
Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation
Shiraishi, D., Fujiwara, Y., Komohara, Y., Mizuta, H., & Takeya, M. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.086 · Cited by 208
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207
Mechanisms of Cell Signaling and Inflammation in Alzheimers Disease
Ho, G., Drego, R., Hakimian, E., & Masliah, E. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010053586237 · Cited by 199
Hoyer, S., Nitsch, R., & Oesterreich, K. (1991) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02251132 · Cited by 196
Kosaraju, J., Gali, C. C., Khatwal, R. B., Dubala, A., Chinni, S., Holsinger, R. M. D., Madhunapantula, V. S. R., Muthureddy Nataraj, S. K., & Basavan, D. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.008 · Cited by 189
Hansen, H. H., Fabricius, K., Barkholt, P., Niehoff, M. L., Morley, J. E., Jelsing, J., Pyke, C., Knudsen, L. B., Farr, S. A., & Vrang, N. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143090 · Cited by 188
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology
Hoozemans, J. J. M., Veerhuis, R., Rozemuller, J. M., & Eikelenboom, P. (2006) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2005.11.001 · Cited by 168
Lund, A., Knop, F. K., & Vilsbøll, T. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.03.005 · Cited by 164
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
D’Amico, M., Filippo, C. D., Marfella, R., Abbatecola, A. M., Ferraraccio, F., Rossi, F., & Paolisso, G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.004 · Cited by 164
Petrov, D., Pedrós, I., Artiach, G., Sureda, F. X., Barroso, E., Pallàs, M., Casadesús, G., Beas-Zarate, C., Carro, E., Ferrer, I., et al. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.004 · Cited by 163
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160
Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P. L., McGeer, E. G., & Hirayama, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00313602 · Cited by 159
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
Wilcox, K. C., Lacor, P. N., Pitt, J., & Klein, W. L. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9691-4 · Cited by 155
Carvalho, C., Cardoso, S., Correia, S. C., Santos, R. X., Santos, M. S., Baldeiras, I., Oliveira, C. R., & Moreira, P. I. (2012) · Diabetes · doi:10.2337/db11-1186 · Cited by 152
Insulin resistance impairs nigrostriatal dopamine function
Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P.-P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 150
Misiak, B., Leszek, J., & Kiejna, A. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.08.003 · Cited by 149
Kosaraju, J., Murthy, V., Khatwal, R. B., Dubala, A., Chinni, S., Muthureddy Nataraj, S. K., & Basavan, D. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12148 · Cited by 146
Parkinson’s disease and enhanced inflammatory response
Stojkovska, I., Wagner, B. M., & Morrison, B. E. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215576313 · Cited by 146
Carvalho, C., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.001 · Cited by 145
Peripheral Hyperinsulinemia Promotes Tau Phosphorylation In Vivo
Freude, S., Plum, L., Schnitker, J., Leeser, U., Udelhoven, M., Krone, W., Bruning, J. C., & Schubert, M. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3343 · Cited by 144
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
Talbot, K., & Wang, H.-Y. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.007 · Cited by 140
Insulin receptor mRNA in the substantia nigra in Parkinson's disease
Takahashi, M., Yamada, T., Tooyama, I., Moroo, I., Kimurâ, H., Yamamoto, T., & Okada, H. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12357-0 · Cited by 137
Hölscher, C. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.009 · Cited by 127
Kornelius, E., Lin, C., Chang, H., Li, H., Huang, W., Yang, Y., Lu, Y., Peng, C., & Huang, C. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12404 · Cited by 123
Insulin resistance in Alzheimer's disease
Dineley, K. T., Jahrling, J. B., & Denner, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.09.001 · Cited by 122
Intranasal Insulin Ameliorates Tau Hyperphosphorylation in a Rat Model of Type 2 Diabetes
Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X., & Gong, C.-X. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121294 · Cited by 120
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Amyloid Precursor Protein Expression Is Upregulated in Adipocytes in Obesity
Lee, Y., Tharp, W. G., Maple, R. L., Nair, S., Permana, P. A., & Pratley, R. E. (2008) · Obesity · doi:10.1038/oby.2008.267 · Cited by 102
Hölscher, C., & Li, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.023 · Cited by 100
Li, L., Zhang, Z., Hölscher, C., Gao, C., Jiang, Y., & Liu, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.005 · Cited by 98
Insulin Has Multiple Antiamyloidogenic Effects on Human Neuronal Cells
Pandini, G., Pace, V., Copani, A., Squatrito, S., Milardi, D., & Vigneri, R. (2013) · Endocrinology · doi:10.1210/en.2012-1661 · Cited by 95
Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C.-X. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130491 · Cited by 91
Inhibition of the Neuronal Insulin Receptor An in Vivo Model for Sporadic Alzheimer Disease?
HOYER, S., LEE, S. K., LÖFFLER, T., & SCHLIEBS, R. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06932.x · Cited by 87
Is Brain Amyloid Production a Cause or a Result of Dementia of The Alzheimer's Type?
Struble, R. G., Ala, T., Patrylo, P. R., Brewer, G. J., & Yan, X.-X. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100846 · Cited by 84
Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
Bomba, M., Ciavardelli, D., Silvestri, E., Canzoniero, L. M., Lattanzio, R., Chiappini, P., Piantelli, M., Di Ilio, C., Consoli, A., & Sensi, S. L. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.139 · Cited by 84
BOYD, A. E., LEBOVITZ, H. E., & FELDMAN, J. M. (1971) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-33-5-829 · Cited by 84
Hölscher, C. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.006 · Cited by 83
HOYER, S., HENNEBERG, N., KNAPP, S., LANNERT, H., & MARTIN, E. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb34448.x · Cited by 73
Mitochondrial efficiency and insulin resistance
Crescenzo, R., Bianco, F., Mazzoli, A., Giacco, A., Liverini, G., & Iossa, S. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2014.00512 · Cited by 72
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 69
PROGRESSION AND PROGNOSIS IN PARKINSONʼS DISEASE
SCHWAB, R. S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196006000-00017 · Cited by 66
Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa
Woert, M. H. V., & Mueller, P. S. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part2360 · Cited by 66
Neuronal insulin signal transduction mechanisms in diabetes phenotypes
Reagan, L. P. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.001 · Cited by 58
Foltynie, T., & Aviles-Olmos, I. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.005 · Cited by 49
Gejl, M., Egefjord, L., Lerche, S., Vang, K., Bibby, B. M., Holst, J. J., Mengel, A., Møller, N., Rungby, J., Brock, B., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.118 · Cited by 49
Kelly, P., McClean, P. L., Ackermann, M., Konerding, M. A., Hölscher, C., & Mitchell, C. A. (2015) · Microcirculation · doi:10.1111/micc.12186 · Cited by 46
Evaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging
Femminella, G. D., & Edison, P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.012 · Cited by 41
Self-citationShie, F.-S., Nivison, M., Hsu, P.-C., & Montine, T. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787458399 · Cited by 41
Mining incretin hormone pathways for novel therapies
Wideman, R. D., & Kieffer, T. J. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.02.005 · Cited by 40
Insulin Neuroprotection and the Mechanisms
Yu, L., & Pei, Y. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.154323 · Cited by 37
Insulin resistance in Alzheimer disease: Is heme oxygenase-1 an Achille's heel?
Barone, E., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.02.013 · Cited by 30
Gejl, M., Rungby, J., Brock, B., & Gjedde, A. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12240 · Cited by 27
Cited by
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Within the brain, endogenous, brain derived GLP-1 can promote insulin release (325, 326), thereby potentially increasing the expression of the internalized IR and IGF-1R in AD patients.”
BackgroundObesity as a risk factor for Alzheimer's disease: weighing the evidence
Alford, S., Patel, D., Perakakis, N., & Mantzoros, C. S. (2018) · Obesity Reviews · doi:10.1111/obr.12629 · Cited by 217
Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Further research is required to identify subtle differences in the intracellular signalling pathways, which may depend on multiple factors including the region of the brain (Calsolaro and Edison, 2015; Grieco et al., 2019; Smith et al., 2019).”
Self-citation
Metadata
- Authors
- Calsolaro, V., & Edison, P.
- Affiliations
- Hammersmith Hospital (GB)
- Corresponding author
- Edison, Paul
- Venue
- CNS Drugs
- Published
- 2015-12
- Volume
- 29
- Issue
- 12
- Pages
- 1023-1039
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2221406620
- Cited by
- 93
- References
- 107
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 9 · 2022: 12 · 2021: 7 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 4
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Drug Discovery Foundation (US)
- Alzheimer’s Research UK (GB)
- Alzheimer's Society (GB)
- Van Geest Foundation
- Medical Research council, UK
- Novo Nordisk (DK)
- GE Healthcare (GB)
- Piramal Life Science
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, GLP-1 analogues, insulin signaling, Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, diabetes mellitus, liraglutide, exenatide, lixisenatide, cognitive function, preclinical drug development
- MeSH terms
- Alzheimer Disease, Animals, Humans, Insulin, Neuroprotective Agents, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.